Finally, the combination of mRNAs encoding interleukin-12, interferon alpha, GM-CSF and interleukin-15 cytokines with immunomodulatory antibodies enhanced the anti-tumor response in both injected and uninjected tumors leading to improved overall survival and higher incidence of complete tumor regressions across several preclinical models. This evidence concerns the gene IL15 and neoplasm.